The company that makes Marlboro cigarettes saw in late 2018 the opportunity to offset declining tobacco sales with a $13 billion investment in Juul, the e-cigarette maker.
That investment has come at a tremendous cost, the latest a $4.1 billion hit announced Thursday by Altria as legal cases against the company continue to mount. That follows a $4.5 billion writedown in October, when Altria slashed the value of its investment in Juul Labs by a third.
Since October, the company said the number of legal cases against Juul have spiked 80%. A wave of vaping illnesses and deaths have raised concerns about the products. The outbreak of vaping-related lung injuries continues, but new cases are on the decline.
More than 2,500 cases of vaping illness have been reported by all 50 states. There have been 54 deaths and more deaths are under investigation.
Tobacco companies like Philip Morris International are attempting to develop new technologies that could serve as an alternative to traditional tobacco use.
Smoking has been declining for more than five decades. Some 42% of U.S. adults smoked in the early 1960s. That was down to 14% in the latest report from the Centers for Disease Control and Prevention.
Efforts to capitalize on new technologies such as e-cigarettes is crucial for for companies like Altria, which took a 35% stake in Juul at the end of 2018. But few saw the risks involved.
The Richmond, Virginia, company on Thursday reported that it had swung to a loss in the fourth quarter from the associated costs, citing burgeoning legal cases that it expects to grow.
It also announced revised terms for its investment in Juul. Juul will restructure its board to include two directors designated by Altria, three independent directors, the Juul CEO and three directors designated by Juul stockholders other than Altria. The board restructuring will take place once Juul receives antitrust clearance from the Federal Trade Commission. Juul will add a nominating committee and a litigation oversight committee to its existing compensation and audit committees once it receives antitrust clearance.
Altria Group Inc. now expects no earnings contributions from Juul through 2022, and it’s lowering its adjusted earnings growth forecast for 2020 through 2022 to between 4% and 7%. It previously had forecast 5% to 8% growth.
For 2020, Altria anticipates adjusted earnings of $4.39 to $4.51 per share. Analysts polled by FactSet predict $4.45 per share.
Shares fell slightly before the market opened.